Core Viewpoint - The article highlights the dedication and contributions of Gao Yaqin, a quality engineer at Betta Pharmaceuticals, who has been instrumental in ensuring the quality of innovative drugs, particularly the first small molecule targeted cancer drug in China, for over fifteen years [1][3]. Group 1: Company Background - Betta Pharmaceuticals was established during a time when generic drugs dominated the market, with a small team focused on developing China's first small molecule targeted anti-cancer drug [3]. - The company successfully launched the drug, Erlotinib Hydrochloride, in 2011, which won the National Science and Technology Progress Award [3]. Group 2: Quality Control Achievements - Gao Yaqin has maintained a 100% accuracy rate in quality inspections over her fifteen-year career, demonstrating exceptional professional skills and experience [6]. - The rigorous quality control processes led to the successful market entry of Erlotinib Hydrochloride, benefiting approximately 700,000 lung cancer patients [6]. Group 3: Problem-Solving and Team Leadership - Gao Yaqin's proactive approach in identifying discrepancies in product data has prevented potential quality issues, showcasing her critical role in the quality assurance process [4]. - She led her team in a thorough investigation to resolve a data anomaly, ensuring that a batch of hundreds of kilograms of medicine was cleared for market release after confirming its quality [6].

Group 1 - The core viewpoint of the news is that Hongdao Investment has conducted research on the listed company Betta Pharmaceuticals, highlighting its financial performance and product pipeline for 2024 [1] - In 2024, Betta Pharmaceuticals is projected to achieve a revenue of 2,891.95 million yuan, representing a year-on-year growth of 17.74%, and a net profit attributable to shareholders of 402.57 million yuan, with a growth of 15.67% [1] - The company has successfully launched five new drugs, including Acetylcysteine, Ensartinib capsules, Bevacizumab, and others, with Bemetanib receiving FDA approval and being included in the NCCN guidelines [1] Group 2 - Betta Pharmaceuticals has invested 717 million yuan in R&D for 2024, accounting for 24.80% of its revenue, with multiple new drug developments progressing smoothly [1] - The company is collaborating with several enterprises to introduce new drugs and expand its R&D pipeline, aiming to build an innovative pharmaceutical ecosystem [1]

Group 1: Beida Pharmaceutical - In 2024, Beida Pharmaceutical achieved operating revenue of 2,891.95 million yuan, a year-on-year increase of 17.74%, and a net profit attributable to shareholders of 402.57 million yuan, up 15.67% year-on-year [1] - The company has launched five new drugs, including Acetylcysteine, Ensartinib capsules, Bevacizumab, and others, with Beimu approved by the FDA and included in the NCCN guidelines [1] - R&D investment for 2024 is 717 million yuan, accounting for 24.80% of revenue, with multiple new drug developments progressing smoothly [1] Group 2: East China Pharmaceutical - East China Pharmaceutical is actively advancing product R&D and market layout across multiple fields, with GLP-1 series products entering Phase III clinical trials, expecting significant results by 2025 [2] - The company has several innovative products in the ADC and PROTAC fields, with some already in clinical stages [2] - East China Pharmaceutical is confident in the overseas medical beauty market and is actively pursuing overseas registration for its medical beauty products [2]